USE OF IL-1 BETA ANTIBODIES IN THE TREATMENT OR PREVENTION OF MYELODYSPLASTIC SYNDROME

摘要

The disclosure relates to the use of an IL-1 beta antibody, especially canakinumab and gevokizumab and biomarkers for the treatment and/or prevention of cancer with myelodysplastic syndrome (MDS)